 | • レポートコード：MRC2304D140 • 出版社/出版日：Transparency Market Research / 2023年1月19日 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、T細胞療法の世界市場を分析し、市場実態を明らかにしています。本書は、エグゼクティブサマリー、市場概要、市場背景、市場動向、疾患別（血液悪性腫瘍、固形腫瘍、その他）分析、治療種類別（CAR T細胞療法、TCRベース、TILベース）分析、モダリティ別（調査、商業化）分析、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ）分析、市場構造分析、競争分析などを収録しています。また、Novartis AG、Merck KGaA、Gilead Sciences Inc.、TCR2 Therapeutics Inc、Bluebird Bio Inc.、Sorrento Therapeutics、Fate Therapeutics、Pfizer Inc.、Amgen、Celgene Corporationなどの企業情報を掲載しています。 ・エグゼクティブサマリー ・市場概要 ・市場背景 ・市場動向 ・世界のT細胞療法市場規模：疾患別 - 血液悪性腫瘍における市場規模 - 固形腫瘍における市場規模 - その他疾患における市場規模 ・世界のT細胞療法市場規模：治療種類別 - CAR T細胞療法の市場規模 - TCRベース治療の市場規模 - TILベース治療の市場規模 ・世界のT細胞療法市場規模：モダリティ別 - 調査における市場規模 - 商業化における市場規模 ・世界のT細胞療法市場規模：地域別 - 北米のT細胞療法市場規模 - 中南米のT細胞療法市場規模 - ヨーロッパのT細胞療法市場規模 - アジア太平洋のT細胞療法市場規模 - 中東・アフリカのT細胞療法市場規模 ・市場構造分析 ・競争分析 |
T-cell Therapy Market – Scope of Report
TMR’s report on the global T-cell therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2033. The report provides revenue of the global T-cell therapy market for the period 2017–2031, considering 2023 as the base year and 2033 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global T-cell therapy market from 2023 to 2033.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the T-cell therapy market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global T-cell therapy market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global T-cell therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global T-cell therapy market.
The report delves into the competitive landscape of the global T-cell therapy market. Key players operating in the global T-cell therapy market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global T-cell therapy market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market T-cell therapy.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global T-cell Therapy Market Analysis 2018-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Bn) Analysis, 2018-2022
4.2. Current and Future Market Size Value (US$ Bn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Indication
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Bn) Analysis By Indication , 2018-2022
5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Indication , 2023-2033
5.3.1. Hematologic Malignancies
5.3.1.1. Lymphoma
5.3.1.2. Leukemia
5.3.1.3. Myeloma
5.3.2. Solid Tumors
5.3.2.1. Melanoma
5.3.2.2. Brain & Central Nervous System
5.3.2.3. Liver Cancer
5.3.2.4. Other Solid Tumors
5.3.3. Other Indications
5.4. Y-o-Y Growth Trend Analysis By Indication , 2018-2022
5.5. Absolute $ Opportunity Analysis By Indication , 2023-2033
6. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Therapy Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Bn) Analysis By Therapy Type, 2018-2022
6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Therapy Type, 2023-2033
6.3.1. CAR T-cell Therapy
6.3.2. T Cell Receptor (TCR)-based
6.3.3. Tumor Infiltrating Lymphocytes (TIL)-based
6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018-2022
6.5. Absolute $ Opportunity Analysis By Therapy Type, 2023-2033
7. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Modality
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Bn) Analysis By Modality , 2018-2022
7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Modality , 2023-2033
7.3.1. Research
7.3.2. Commercialized
7.4. Y-o-Y Growth Trend Analysis By Modality , 2018-2022
7.5. Absolute $ Opportunity Analysis By Modality , 2023-2033
8. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2018-2022
8.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2023-2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
9.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
9.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Indication
9.2.3. By Therapy Type
9.2.4. By Modality
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Indication
9.3.3. By Therapy Type
9.3.4. By Modality
9.4. Key Takeaways
10. Latin America T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
10.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Indication
10.2.3. By Therapy Type
10.2.4. By Modality
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Indication
10.3.3. By Therapy Type
10.3.4. By Modality
10.4. Key Takeaways
11. Europe T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. U.K.
11.2.1.5. Spain
11.2.1.6. Russia
11.2.1.7. Rest of Europe
11.2.2. By Indication
11.2.3. By Therapy Type
11.2.4. By Modality
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Indication
11.3.3. By Therapy Type
11.3.4. By Modality
11.4. Key Takeaways
12. Asia Pacific T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. India
12.2.1.4. South Korea
12.2.1.5. Australia
12.2.1.6. Rest of APAC
12.2.2. By Indication
12.2.3. By Therapy Type
12.2.4. By Modality
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Indication
12.3.3. By Therapy Type
12.3.4. By Modality
12.4. Key Takeaways
13. MEA T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033
13.2.1. By Country
13.2.1.1. South Africa
13.2.1.2. Saudi Arabia
13.2.1.3. UAE
13.2.1.4. Israel
13.2.1.5. Rest of MEA
13.2.2. By Indication
13.2.3. By Therapy Type
13.2.4. By Modality
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Indication
13.3.3. By Therapy Type
13.3.4. By Modality
13.4. Key Takeaways
14. Key Countries T-cell Therapy Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Indication
14.1.2.2. By Therapy Type
14.1.2.3. By Modality
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Indication
14.2.2.2. By Therapy Type
14.2.2.3. By Modality
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Indication
14.3.2.2. By Therapy Type
14.3.2.3. By Modality
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Indication
14.4.2.2. By Therapy Type
14.4.2.3. By Modality
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Indication
14.5.2.2. By Therapy Type
14.5.2.3. By Modality
14.6. Italy
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Indication
14.6.2.2. By Therapy Type
14.6.2.3. By Modality
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Indication
14.7.2.2. By Therapy Type
14.7.2.3. By Modality
14.8. U.K.
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Indication
14.8.2.2. By Therapy Type
14.8.2.3. By Modality
14.9. Spain
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Indication
14.9.2.2. By Therapy Type
14.9.2.3. By Modality
14.10. Russia
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Indication
14.10.2.2. By Therapy Type
14.10.2.3. By Modality
14.11. China
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Indication
14.11.2.2. By Therapy Type
14.11.2.3. By Modality
14.12. Japan
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Indication
14.12.2.2. By Therapy Type
14.12.2.3. By Modality
14.13. India
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Indication
14.13.2.2. By Therapy Type
14.13.2.3. By Modality
14.14. South Korea
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Indication
14.14.2.2. By Therapy Type
14.14.2.3. By Modality
14.15. Australia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Indication
14.15.2.2. By Therapy Type
14.15.2.3. By Modality
14.16. South Africa
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Indication
14.16.2.2. By Therapy Type
14.16.2.3. By Modality
14.17. Saudi Arabia
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Indication
14.17.2.2. By Therapy Type
14.17.2.3. By Modality
14.18. UAE
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Indication
14.18.2.2. By Therapy Type
14.18.2.3. By Modality
14.19. Israel
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Indication
14.19.2.2. By Therapy Type
14.19.2.3. By Modality
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Indication
15.3.3. By Therapy Type
15.3.4. By Modality
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Novartis AG
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.1.5.2. Product Strategy
16.1.1.5.3. Channel Strategy
16.1.2. Merck KGaA
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.2.5.2. Product Strategy
16.1.2.5.3. Channel Strategy
16.1.3. Gilead Sciences Inc.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.3.5.2. Product Strategy
16.1.3.5.3. Channel Strategy
16.1.4. TCR2 Therapeutics Inc
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.4.5.2. Product Strategy
16.1.4.5.3. Channel Strategy
16.1.5. Bluebird Bio Inc
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.5.5.2. Product Strategy
16.1.5.5.3. Channel Strategy
16.1.6. Sorrento Therapeutics
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.6.5.2. Product Strategy
16.1.6.5.3. Channel Strategy
16.1.7. Fate Therapeutics
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.7.5.2. Product Strategy
16.1.7.5.3. Channel Strategy
16.1.8. Pfizer Inc
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.8.5.2. Product Strategy
16.1.8.5.3. Channel Strategy
16.1.9. Amgen
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.9.5.2. Product Strategy
16.1.9.5.3. Channel Strategy
16.1.10. Celgene Corporation
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.10.5.2. Product Strategy
16.1.10.5.3. Channel Strategy
17. Assumptions & Acronyms Used
18. Research Methodology